Lawyers Accuse J&J and Bayer of Withholding Xarelto Study Data
More Info: Defective Drugs
Lawyers for patients suing Johnson & Johnson and Bayer over severe bleeding injuries caused by the blockbuster blood thinner Xarelto say the drug makers failed to provide clinical trial data, the New York Times reported.
Documents filed in court say a re-analysis conducted by Duke published by the New England Medical Journal of Medicine was missing key information that could have affected clinical trial data comparing Xarelto to warfarin in its 2011 ROCKET-AF study. J&J and Bayer stayed silent and helped deceive editors of the journal, lawyers said.
The trial in question compared the safety of Xarelto and warfarin. Specifically, it collected data on the number of strokes and bleeding events experienced by patients taking one drug or the other. According to the study results, both Xarelto and warfarin had the same risk of bleeding, but J&J and Bayer’s drug showed fewer incidents of bleeding in the brain and fatal bleeding.
See the full, original post here: https://www.drugwatch.com/news/2016/03/09/lawyers-accuse-jj-bayer-withholding-xarelto-study-data/
TriMark Legal Funding was founded in 2003 and is one of America's original lawsuit funding companies. TriMark provides pre-settlement loans and post-settlement loans to injured plaintiffs who are involved in personal injury lawsuits, employment litigation, work injury accidents and workers compensation settlement funding, mass tort litigation, and multidistrict litigation. We also provide loans for lawyers and law firm portfolio funding.
|Mass Torts||Other MDL|
Click here to see the original article.